A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer
18 Years
N/A
Male
Prostate Cancer
Trial Information
A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer
Tetrathiomolybdate or TM, a drug developed for Wilson's Disease, removes copper from the
bloodstream. Copper is a key factor in angiogenesis (blood vessel growth)- a process that
occurs normally in the body but becomes uncontrolled in cancerous cells. Tetrathiomolybdate
essentially wages war against copper, which serves to choke off tumor growth. Realizing the
key role of copper in angiogenesis, researchers have begun exploring treatment with
Tetrathiomolybdate for different types of cancers. This clinical trial will evaluate the
effectiveness of Tetrathiomolybdate in the treatment of patients with hormone refractory
prostate cancer. Hormone refractory prostate cancer refers to advanced disease in which the
patient no longer responding to conventional hormonal treatment.
Inclusion Criteria
Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression
following hormonal therapy and antiandrogen withdrawal.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the time to progression and pattern of progression of prostate cancer in patients with androgen-independent prostate cancer treated with tetrathiomolybdate.
Principal Investigator
David C. Smith, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
The University of Michigan Comprehensive Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
UMCC 9962
NCT ID:
NCT00150995
Start Date:
May 2001
Completion Date:
Related Keywords:
- Prostate Cancer
- Prostatic Neoplasms
Name | Location |
|---|---|
| The University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109 |
